Predict falls by mapping movements
- Trial ID
- NCT06405334
- Official Title
- Kinematic and Neural Dynamics of Postural Instability in Parkinson's Disease
- Goal
- Predict falls by mapping movements
- Status
- RECRUITING
- Sponsor
- VA Office of Research and Development
- Study Type
- OBSERVATIONAL
- Enrollment
- 100 participants
- Conditions
- Parkinson's Disease
Plain-Language Summary
The goal is to map the movement patterns and brain signals that lead to balance problems and falls in people with Parkinson's, so future tests or treatments can better predict and prevent instability. Researchers will record body movements during balance tests with motion sensors and clinical measures, and for Veterans who already have a Percept-enabled subthalamic nucleus deep brain stimulator they will also capture the device's neural recordings to link specific brain activity to instability. This is observational, so it will not change your current Parkinson's treatments. The study is enrolling Veterans aged 18 and up with clinician-diagnosed Parkinson's in Hoehn and Yahr stage 2 or 3 who can consent; people with other parkinsonism disorders, significant dementia that prevents consent, symptomatic orthostatic hypotension, or who are past stage 3 are excluded, and Aim 3 specifically requires an implanted STN DBS with a Percept device.
Locations
- Minneapolis VA Health Care System, Minneapolis, MN, Minneapolis, Minnesota, United States
Frequently Asked Questions
- What is this trial testing?
- This trial is studying an experimental treatment. The goal is to map the movement patterns and brain signals that lead to balance problems and falls in people with Parkinson's, so future tests or treatments can better predict and prevent instability. Researchers will record body movements during balance tests with motion sensors and clinical measures, and for Veterans who already have a Percept-enabled subthalamic nucleus deep brain stimulator they will also capture the device's neural recordings to link specific brain activity to instability. This is observational, so it will not change your current Parkinson's treatments. The study is enrolling Veterans aged 18 and up with clinician-diagnosed Parkinson's in Hoehn and Yahr stage 2 or 3 who can consent; people with other parkinsonism disorders, significant dementia that prevents consent, symptomatic orthostatic hypotension, or who are past stage 3 are excluded, and Aim 3 specifically requires an implanted STN DBS with a Percept device.
- Who can participate?
- Participants must be at least 18 Years.
- Where is this trial located?
- This trial is recruiting at 1 location.
- Does it cost anything to join?
- No. There is no cost to participate. Study-related care and treatment are provided at no charge.
- How long does the trial last?
- This trial is estimated to last approximately 4 years.